Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aurobindo Pharma has received marketing and manufacturing approval from the US Food and Drug Administration (FDA) for Divalproex Sodium delayed - release tablets USP 125mg, 250mg and 500mg.
Subscribe to our email newsletter
Depakote delayed-release tablets falls under the central nervous system (CNS) therapeutic category as a treatment for the manic episodes associated with bipolar disorder.
They are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures and for prophylaxis of migraine headaches.
Divalproex Sodium delayed – release tablets USP 125mg, 250mg and 500mg are the generic version Abbott Laboratories’ Depakote delayed-release tablets USP 125mg, 250mg and 500mg.